Bridgewater Associates LP Trims Holdings in Inari Medical, Inc. (NASDAQ:NARI)

Bridgewater Associates LP reduced its holdings in shares of Inari Medical, Inc. (NASDAQ:NARI) by 30.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,730 shares of the company’s stock after selling 2,478 shares during the period. Bridgewater Associates LP’s holdings in Inari Medical were worth $293,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Norges Bank purchased a new position in Inari Medical during the fourth quarter valued at $14,447,000. Jennison Associates LLC raised its holdings in Inari Medical by 11.8% in the fourth quarter. Jennison Associates LLC now owns 1,763,258 shares of the company’s stock worth $90,014,000 after buying an additional 186,617 shares during the last quarter. Evoke Wealth LLC grew its holdings in shares of Inari Medical by 207.5% during the fourth quarter. Evoke Wealth LLC now owns 192,926 shares of the company’s stock valued at $9,849,000 after buying an additional 130,186 shares during the last quarter. American Century Companies Inc. lifted its position in Inari Medical by 9.1% in the 4th quarter. American Century Companies Inc. now owns 1,068,487 shares of the company’s stock valued at $54,546,000 after acquiring an additional 89,108 shares in the last quarter. Finally, Lisanti Capital Growth LLC purchased a new stake in Inari Medical during the 4th quarter valued at $3,969,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Inari Medical Stock Performance

NARI stock opened at $79.97 on Monday. The company has a market capitalization of $4.68 billion, a PE ratio of -59.24 and a beta of 1.02. The company’s fifty day moving average price is $79.97 and its 200-day moving average price is $65.81. Inari Medical, Inc. has a one year low of $36.73 and a one year high of $79.99.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Piper Sandler upped their target price on shares of Inari Medical from $52.00 to $80.00 and gave the company a “neutral” rating in a research note on Tuesday, January 7th. Baird R W cut Inari Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 7th. William Blair reaffirmed a “market perform” rating on shares of Inari Medical in a report on Tuesday, January 7th. Wells Fargo & Company reissued an “equal weight” rating and issued a $80.00 target price (up previously from $65.00) on shares of Inari Medical in a report on Tuesday, January 7th. Finally, Canaccord Genuity Group reaffirmed a “hold” rating and set a $80.00 price target (up previously from $74.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Twelve equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Inari Medical currently has an average rating of “Hold” and a consensus target price of $68.00.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.